PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 72.55

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.23M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 87.57B
HLN Haleon plc

N/A

USD 45.67B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 45.20B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.38B
CTLT Catalent Inc

N/A

USD 10.94B
ELAN Elanco Animal Health

N/A

USD 6.34B
BHC Bausch Health Companies Inc

N/A

USD 3.00B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.66B
CPHI China Pharma Holdings Inc

N/A

USD 4.27M
YCBD cbdMD Inc

N/A

USD 1.92M

ETFs Containing PBH

NDIA Global X Funds 3.65 % 0.00 %

N/A

USD 0.03B
XST:CA iShares S&P/TSX Capped Co.. 3.17 % 0.61 %

N/A

CAD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.51% 60% D- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.51% 60% D- 74% C
Trailing 12 Months  
Capital Gain 21.57% 47% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.57% 47% F 57% F
Trailing 5 Years  
Capital Gain 101.25% 93% A 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 101.25% 93% A 84% B
Average Annual (5 Year Horizon)  
Capital Gain 16.38% 93% A 79% B-
Dividend Return 16.38% 93% A 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.20% 73% C 49% F
Risk Adjusted Return 77.23% 100% F 88% B+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector